Conformis Closes Initial Public Offering

Bedford, Mass. – July 7, 2015 – Conformis, Inc. (NASDAQ: CFMS) announced today the closing of its initial public offering of 10,350,000 shares of common stock at a public offering price of $15.00 per share, before underwriting discounts, including 1,350,000 shares of common stock issued upon the exercise in full by the underwriters of their option to purchase additional shares at the public offering price, less the underwriting discount.

J.P. Morgan and Deutsche Bank Securities acted as joint book-running managers for the offering. Wells Fargo Securities, Canaccord Genuity and Oppenheimer & Co. acted as co-managers.

A registration statement relating to these securities was declared effective by the Securities and Exchange Commission on June 30, 2015. A copy of the final prospectus relating to this offering may be obtained from: J.P. Morgan Securities LLC, Attention: Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by telephone at (866) 803-9204; or Deutsche Bank Securities Inc., Attention: Prospectus Group, 60 Wall Street, New York, NY 10005-2836, or by email to prospectus.cpdg@db.com, or by telephone at +1 (800) 503-4611.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy, nor shall there be any sale of, these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification of these securities under the securities laws of any such state or jurisdiction.

About Conformis, Inc.
Conformis is a medical technology company that uses its proprietary iFit Image-to-Implant technology platform to develop, manufacture and sell joint replacement implants that are individually sized and shaped, or customized, to fit each patient’s unique anatomy. Conformis offers a broad line of customized knee implants designed to restore the natural shape of a patient’s knee.

Investor Contact:
Paul Weiner
ir@conformis.com
(781) 345-9001

Media Contacts:
Bill Berry
Berry & Company Public Relations
Bberry@berrypr.com
(212) 253-8881

Lynn Granito
Berry & Company Public Relations
Lgranito@berrypr.com
(212) 253-8881